<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:department>Medical Statistics and Health Evaluation</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9917BD78-B5E1-46F4-85DE-5324E83419B2"><gtr:id>9917BD78-B5E1-46F4-85DE-5324E83419B2</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:surname>Jacoby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FE6E2523-AFDD-4BC9-93E2-561E1B55AFE1"><gtr:id>FE6E2523-AFDD-4BC9-93E2-561E1B55AFE1</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Neoptolemos</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/7AAC0F13-7669-495E-8826-6AAE0106F0D4"><gtr:id>7AAC0F13-7669-495E-8826-6AAE0106F0D4</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Guy</gtr:otherNames><gtr:surname>Marson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9C45956A-2272-47ED-BADE-FBA5EEC51888"><gtr:id>9C45956A-2272-47ED-BADE-FBA5EEC51888</gtr:id><gtr:firstName>Dyfrig</gtr:firstName><gtr:otherNames>Arwyn</gtr:otherNames><gtr:surname>Hughes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/54ED1134-08E1-4E26-B129-C408999E1CE6"><gtr:id>54ED1134-08E1-4E26-B129-C408999E1CE6</gtr:id><gtr:firstName>Rosalind</gtr:firstName><gtr:surname>Smyth</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/85AB4A3B-4440-44C5-8065-7E9105C8B112"><gtr:id>85AB4A3B-4440-44C5-8065-7E9105C8B112</gtr:id><gtr:firstName>Carrol</gtr:firstName><gtr:surname>Gamble</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/150DF05A-FF1F-446E-86FD-4E68FCDA59C6"><gtr:id>150DF05A-FF1F-446E-86FD-4E68FCDA59C6</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Whitehead</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77CC8C52-1D64-4172-B62E-6FBADDF7BF8F"><gtr:id>77CC8C52-1D64-4172-B62E-6FBADDF7BF8F</gtr:id><gtr:firstName>Catrin</gtr:firstName><gtr:surname>Tudur Smith</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/57775794-FAE1-4C5E-BCA9-5D06A3F60E32"><gtr:id>57775794-FAE1-4C5E-BCA9-5D06A3F60E32</gtr:id><gtr:firstName>Bridget</gtr:firstName><gtr:surname>Young</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/E7E0FD44-2BF4-4517-AC8D-F13A255A0017"><gtr:id>E7E0FD44-2BF4-4517-AC8D-F13A255A0017</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Bower</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77F021F2-CB59-421B-9A71-664FE2218FBD"><gtr:id>77F021F2-CB59-421B-9A71-664FE2218FBD</gtr:id><gtr:firstName>Munir</gtr:firstName><gtr:surname>Pirmohamed</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C5D38AFF-0D8F-4D11-B91B-7954A21AF259"><gtr:id>C5D38AFF-0D8F-4D11-B91B-7954A21AF259</gtr:id><gtr:firstName>Paula</gtr:firstName><gtr:surname>Williamson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9524247D-B9C5-4462-9F7E-240268A13CD2"><gtr:id>9524247D-B9C5-4462-9F7E-240268A13CD2</gtr:id><gtr:firstName>Patricia</gtr:firstName><gtr:otherNames>Anne</gtr:otherNames><gtr:surname>Whitehead</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800792"><gtr:id>059B90EB-105D-452A-BB33-51ADD5F2A1E2</gtr:id><gtr:title>North West HTMR</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800792</gtr:grantReference><gtr:abstractText>The best method for finding out whether one treatment is better than another is to perform a research study known as a randomised controlled trial, in which treatments are allocated to patients at random, rather like throwing a dice to decide. Studies like this are not without their difficulties. For example, when drugs are first trialled, the research should proceed in stages with evaluation at each stage. As treatments move into the later phases of study, researchers must choose which outcomes are most important to measure, a decision ideally arrived at through consideration of both the clinical and patient perspective. This proposal is to create a world-class centre where issues such as these facing the clinical trials community can be investigated, the overall aim being to improve patient care by improving the evidence on which decisions about healthcare are based.</gtr:abstractText><gtr:technicalSummary>The gold standard study design for determining efficacy of a treatment is the randomised controlled trial (RCT) but trials are not without their difficulties (Prescott et al, 1999). This proposal is to create a world-class centre where methodological issues facing the clinical trials community can be investigated, the overall aim being to improve patient care by improving the validity and relevance of the healthcare evidence base. This will include provision of a training programme that will deliver individuals with the capacity to be leading clinical trialists and methodologists. 

The Hub will focus on selected methodological research themes, initially developing and translating the methods for application across four clinical areas. The methodological areas include the promotion, modification and implementation of recently devised methods for improving the efficiency of a wide variety of early phase trials, the enhancement of the link between the findings of systematic reviews and the design of later phase trials particularly in relation to outcome selection (Clarke 2007, Sinha 2008), the development and application of methods of adjustment for non-compliance in both clinical and cost effectiveness analyses, and ensuring that the design and conduct of trials over their entire lifecourse is informed by evidence on the perspectives of patients. This will enable the design, interpretation, and dissemination of the results of RCTs that are of greater relevance to stakeholders.</gtr:technicalSummary><gtr:fund><gtr:end>2014-01-29</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2910720</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>COMET Initiative</gtr:description><gtr:id>BB554021-DDE0-474E-ABE6-71D67A527038</gtr:id><gtr:impact>COMET Initiative Launch meeting, Liverpool 2010
2nd meeting of the COMET Initiative, Bristol 2011
Design and launch of the COMET Initiative website 2011
COMET Initiative blog series established with the BMJ
Advice on core outcomes informed NICE 2011 epilepsy guidelines
COMET featured on the homepage of the NIHR website
Addition to NIHR HTA application form, explicitly referencing importance of core outcomes sets, the COMET Initiative and website</gtr:impact><gtr:outcomeId>mVX55uo3DVz-3</gtr:outcomeId><gtr:partnerContribution>Member of the COMET Initiative Management GroupMember of the COMET Initiative Management GroupMember of the COMET Initiative Management Group</gtr:partnerContribution><gtr:piContribution>Led in the set up of the COMET Initiative with collaboration from colleagues in the All-Ireland HTMR, Conduct HTMR and University of Oxford. A joint grant application was made by the four collaborating centres to the MRC Network of Hubs for Trials Methodology Research and &amp;pound;50000 was awarded.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC ConDuCT Trials Methodology Hub</gtr:department><gtr:description>COMET Initiative</gtr:description><gtr:id>DF8837EB-C5B2-417E-98F3-D5BC6DBDDEF8</gtr:id><gtr:impact>COMET Initiative Launch meeting, Liverpool 2010
2nd meeting of the COMET Initiative, Bristol 2011
Design and launch of the COMET Initiative website 2011
COMET Initiative blog series established with the BMJ
Advice on core outcomes informed NICE 2011 epilepsy guidelines
COMET featured on the homepage of the NIHR website
Addition to NIHR HTA application form, explicitly referencing importance of core outcomes sets, the COMET Initiative and website</gtr:impact><gtr:outcomeId>mVX55uo3DVz-2</gtr:outcomeId><gtr:partnerContribution>Member of the COMET Initiative Management GroupMember of the COMET Initiative Management GroupMember of the COMET Initiative Management Group</gtr:partnerContribution><gtr:piContribution>Led in the set up of the COMET Initiative with collaboration from colleagues in the All-Ireland HTMR, Conduct HTMR and University of Oxford. A joint grant application was made by the four collaborating centres to the MRC Network of Hubs for Trials Methodology Research and &amp;pound;50000 was awarded.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC All-Ireland Hub for Trials Methodology Research</gtr:department><gtr:description>COMET Initiative</gtr:description><gtr:id>2C2D7C26-832F-4725-8531-7A1E49F6B76A</gtr:id><gtr:impact>COMET Initiative Launch meeting, Liverpool 2010
2nd meeting of the COMET Initiative, Bristol 2011
Design and launch of the COMET Initiative website 2011
COMET Initiative blog series established with the BMJ
Advice on core outcomes informed NICE 2011 epilepsy guidelines
COMET featured on the homepage of the NIHR website
Addition to NIHR HTA application form, explicitly referencing importance of core outcomes sets, the COMET Initiative and website</gtr:impact><gtr:outcomeId>mVX55uo3DVz-1</gtr:outcomeId><gtr:partnerContribution>Member of the COMET Initiative Management GroupMember of the COMET Initiative Management GroupMember of the COMET Initiative Management Group</gtr:partnerContribution><gtr:piContribution>Led in the set up of the COMET Initiative with collaboration from colleagues in the All-Ireland HTMR, Conduct HTMR and University of Oxford. A joint grant application was made by the four collaborating centres to the MRC Network of Hubs for Trials Methodology Research and &amp;pound;50000 was awarded.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk, Germany 2014 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C5E2FB8C-45F6-49F6-B9BD-9D5DF28790FD</gtr:id><gtr:impact>Wider dissemination of work

None at present</gtr:impact><gtr:outcomeId>54576e0b938c85.44027469</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint modelling talk, London 2013 RKD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0EB34F34-933D-47BE-94B3-7762F3CDFF90</gtr:id><gtr:impact>50-60 participants. The talk was followed by a lively discussion where participants discussed applying the methods in their clinical and biolomedical research.

Several participants approached to discuss their projects involving longitudinal data and requested the software JoineR.</gtr:impact><gtr:outcomeId>NfG12izZ6Qo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ORBIT workshop / presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B1D771AC-11DA-4A3F-888D-A5F88AC3CA49</gtr:id><gtr:impact>Members of the research team have presented the findings at several national and international research meetings. During the project, the ORBIT workshop was developed and delivered, usually by three of the team, at several Cochrane meetings (Dublin, Freiburg, Edinburgh, Halifax, Singapore). The workshop includes a small group exercise, in which participants read trial reports and use our classification system to determine the likelihood of outcome reporting bias. The examples we use are chosen to illustrate a variety of classifications and are taken from systematic reviews where we have obtained the information from the trialist themselves. The workshop also demonstrates how our classification of the risk of outcome reporting bias helps to assess the related dimension in the new 'Risk of bias' tool being used by the Cochrane Collaboration. The presentations have focussed on both the prevalence and impact of outcome reporting bias in a large unselected cohort of Cochrane systematic reviews (see BMJ publication) and interviews with trialists to understand the reasons for discrepancies between outcomes specified in the trial protocol and those reported in the study publication (submitted to BMJ).

The feedback evaluations received from the most recent workshop have been extremely positive with all participants finding the workshop useful, and 60-75% finding it very useful. Recently, the Cochrane Bias Methods Group designated this a 'core' workshop which enabled one of our team to attend the Cochrane Colloquium in Singapore for free.</gtr:impact><gtr:outcomeId>3A18737F7B9</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Berlin 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>92B366CB-5358-4F8A-B0BC-D05EC4F57073</gtr:id><gtr:impact>Medical statisticians attended a talk presenting the results of methodological research.

Methods have now been implemented in open-source R package upon request from audience.</gtr:impact><gtr:outcomeId>cMVmTnAkwGn</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cochrane Conference presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ADF7C446-E7F1-4F85-A5C4-4B333B7313FB</gtr:id><gtr:impact>Consumers attended workshop.

Well received.</gtr:impact><gtr:outcomeId>AB753216F00</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Warwick 2012 TJ</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A400A867-55D7-4F41-907C-4A59DD5E010F</gtr:id><gtr:impact>It has allowed wider dissemination of the work

Joint research with the Warwick group</gtr:impact><gtr:outcomeId>QtBF9wwrWqD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit - Wirral</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>47C29ADF-0D08-45EE-A4A0-D31D6493E681</gtr:id><gtr:impact>A talk about clinical trials

Teacher fedback that it was well received by students.</gtr:impact><gtr:outcomeId>0F8DFD9D4C7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>JoineR Workshop 2013, Newcastle RKD</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E5E639C2-FD87-4575-B765-1ADE841EF19B</gtr:id><gtr:impact>13 participants. The workshop was interactive throughout where participants discuss applying the methods in their clinical data, and had hands-on experience in using the software JoineR.

The workshop has received very positive feedback. All participants considered use of joint modelling in their future research and improved their understanding of the relevance of joint modelling ideas to substantive clinical research.</gtr:impact><gtr:outcomeId>GfHjsPxvBRe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NRES training day 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D0B41D95-2703-448E-90BE-B88D45E85D43</gtr:id><gtr:impact>Presented findings from RECRUIT and CACE on children and young people's perspectives on recruitment to clinical trials at National Research Ethics Service Training Day, November 2011.

Aimed to help ethics committee members understand what is (and is not) important to young people when they are approached about entering a clinical trial</gtr:impact><gtr:outcomeId>Fd614ad3HJM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Neonatal and Midwifery Collaboration on Research Delivery meeting Birmingham 2015 (BY)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>87FD4A8C-266D-4ED2-BDE2-E89B328A9BCF</gtr:id><gtr:impact>Dissemination of Hub research particularly RECRUIT study</gtr:impact><gtr:outcomeId>567a6564d748a7.87911092</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Florence 2014 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EEB9A544-AE2E-438D-9508-0D8051E8BDBA</gtr:id><gtr:impact>Wider dissemination of work

None at present</gtr:impact><gtr:outcomeId>54576eb6da98b2.80876374</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 35th Conference of the International Society for Clinical Biostatistics 2014 (WYY)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3E4916DF-2821-4A69-9DD8-90CDDAB2A0E9</gtr:id><gtr:impact>Wider dissemination of work


None at present</gtr:impact><gtr:outcomeId>54576f61ebce75.80505049</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET talk, Exploiting Existing Data for Health Research&quot; 4th?International Conference hosted by the Scottish Health Informatics Programme in association with the four UK Ehealth Informatics Research Centres, St Andrews, 2013 (PW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7CC1BB39-82AB-429B-9F97-35E82EAADEE7</gtr:id><gtr:impact>Abstract accepted for oral presentation.

Opened up a new area of interest.</gtr:impact><gtr:outcomeId>VGPPGcKviTf</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Southampton 2012 KP</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CFCC41F5-3155-46CE-8DDD-70D44A08A826</gtr:id><gtr:impact>This was a national talk for all PhD students in Statistics, including some participants from Europe.

This talk included students from outside of the medical statistics background to understand different contexts for methodology and input into the methodological aspects was offered.</gtr:impact><gtr:outcomeId>gN7rEfgjxJu</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, MRC/NIHR Methods Fellows Meeting 2014 (RE)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D9C6D542-27AA-4F95-9190-2B5DD2AD44A6</gtr:id><gtr:impact>Discussion with audience about MRC career's options, and stratified medicine research


Collaboration with Newcastle around methodology work</gtr:impact><gtr:outcomeId>546076606edae8.08579124</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 35th Conference of the International Society for Clinical Biostatistics 2014 (AC)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6F70B0BC-DC54-49B3-8493-3EC50510E6DE</gtr:id><gtr:impact>Wider dissemination of work


None at present</gtr:impact><gtr:outcomeId>54576f2484be14.78777425</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop, Bangor 2013 DH</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A22C118C-E047-4361-ACCC-4F07A07BD8B3</gtr:id><gtr:impact>The aim of the workshop was to develop a research agenda on the assessment of benefits in relation to harm in the context of health technology assessment

Draft paper in preparation</gtr:impact><gtr:outcomeId>VPxkVKSkUsE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 35th Conference of the International Society for Clinical Biostatistics (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>02F20802-D1FC-4C17-B945-A0792A29D563</gtr:id><gtr:impact>Wider dissemination of work


Discussions about implementation of method with a CRO</gtr:impact><gtr:outcomeId>54576fc79a2598.82864412</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Institute of Population Health Postgraduate showcase 2014 (AHM)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9C710515-5151-40A0-ABFF-659D43A5502F</gtr:id><gtr:impact>Discussion

Not aware of any notable impacts</gtr:impact><gtr:outcomeId>54588d9641ae42.08287575</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET talk, Workshop on the methods for benefit-risk analysis in drug regulation and health technology assessment, Bangor, Jan 2013 (PW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>82486C92-E90C-46FA-856A-2C7F2C43F3D5</gtr:id><gtr:impact>Delivered to specialist audience, increased awareness and interest in the COMET Initiative.

Further discussions.</gtr:impact><gtr:outcomeId>S7LL7HWUGte</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop, Manchester 2012 PW</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CC2ECDA5-66B7-4630-8ED6-9DC21664F2E4</gtr:id><gtr:impact>38 leading trialists attended a workshop and explored greater clinical collaboration on methodological issues in trials

Following the meeting suggestions were received from participants on how clinical engagement can be increased, in particular engagement with ACFs.</gtr:impact><gtr:outcomeId>Cmk9X9Gadhb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, PSI 2012 TJ</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9E36A916-BEF2-484A-B2E3-579D5387BC92</gtr:id><gtr:impact>It has allowed wider dissemination of the work

Some discussions on using our methods in different studies</gtr:impact><gtr:outcomeId>KxhXSrwGvoX</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Manchester 2012 KP</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E7AF8675-4956-4CAB-B933-F4D07AB4B789</gtr:id><gtr:impact>This was a national talk for all MRC hub associated PhD students allowing communication between PhD students between different institutions

The talk was well received and allowed communication between PhD students between different institutions.</gtr:impact><gtr:outcomeId>J8WvhoEsykR</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 16th Annual J&amp;J Pharma Statistics Conference (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B53318DB-095F-4847-95D7-69E0067D163B</gtr:id><gtr:impact>Wider dissemination of work


Discussions about implementation of method with Janssen Pharmaceutica</gtr:impact><gtr:outcomeId>545770814d4cd7.77085440</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Joint modelling talk, Budapest 2013 RKD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8C2BEDBC-5064-426D-BE7B-7869421261CD</gtr:id><gtr:impact>30-40 participants. The talk was followed by a lively discussion where participants discussed applying the methods in their clinical and biolomedical research.

Requests for the software JoineR.</gtr:impact><gtr:outcomeId>FmugRhNgpT4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET talk, ECRIN 2013 PW</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B1C947D0-69C8-4671-9FAD-B2A911AEDA73</gtr:id><gtr:impact>The aims and progress of the COMET Initiative were described

The talk raised awareness amongst international clinical research groups</gtr:impact><gtr:outcomeId>S43QpgM6wRi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET workshop, Kyoto, Japan, 2013 (PW, MC and LG)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A3A42587-6BA3-4465-A9DC-5B19654A564B</gtr:id><gtr:impact>2 day workshop delivered, attended by approximately 100 individuals from all over Japan.

Introduced Japanese researchers to the COMET Initiative and the idea of core outcome sets. Recieved excellent feedback and was very well received. On-going discussion regarding possibility of future collaboration.</gtr:impact><gtr:outcomeId>DHPBC5bDnVV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>JLA teleconference 2012</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>725BBD8A-7EB5-497C-B7C3-E89CD4280A06</gtr:id><gtr:impact>A teleconference was held following a request for advice from NICE and JLA about COMET and methods for core outcome set development.

Agreement to work in partnership.</gtr:impact><gtr:outcomeId>b37j9zgJ2cL</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Mini Symposium on alternative methods for dose-finding and dose-ranging trials 2015 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>785F094A-3D47-4BCF-BAFE-996FF7F3B82F</gtr:id><gtr:impact>Raising profile of Hub; Dissemination of hub research


Has led to Merck adopting a model based approach to dose finding for the first time</gtr:impact><gtr:outcomeId>567a66d87e3568.21427966</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET talk, Network of Hubs for Trials Methodology Annual Meeting, Oxford, 2013 (LG)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>23538183-E6FE-437B-BF59-FB6366062C83</gtr:id><gtr:impact>Talk delivered. Question and answer session.

Slides of presentation shared.</gtr:impact><gtr:outcomeId>BtUD9MCdswW</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, RSS 2012 TJ</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BD81E4E3-CC9F-4DDC-9089-BE1BE0F22DD1</gtr:id><gtr:impact>It has allowed wider dissemination of the work

Some discussion on using our methods in a study</gtr:impact><gtr:outcomeId>skDn9bMsjj9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET workshop, NICE 2011</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>EB0793C1-6D30-4B41-A6A3-3DF5B36BC18E</gtr:id><gtr:impact>A COMET workshop was delivered at a National Institute for Health and Clinical Excellence (NICE) National Collaborating Centres (NCC) Technical Meeting. This was attended by over 40 participants involved in the NICE guideline development process. The objectives of the workshop were to identify problems with outcomes in clinical trials and the subsequent impact for systematic reviews/reviewers and guidelines/guideline developers, and to consider core outcome sets as a solution to these problems. The workshop included formal presentation, group exercise and discussion.

We were approached by the programme manager for the Patient and Public Involvement programme at NICE, who runs workshops with patients, who asked if they could use one of the examples from the group exercise in their workshops with patients, as it would be a great way of getting patients to think about outcomes.</gtr:impact><gtr:outcomeId>EWyL9DS6XZN</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET talk, HSRN Symposium 2013, UK (PW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F871EC30-B265-4F0B-878A-D595ABCB8354</gtr:id><gtr:impact>Abstract selected for oral presentation.

Not known yet.</gtr:impact><gtr:outcomeId>EWScBXaN6Z6</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 35th Conference of the International Society for Clinical Biostatistics 2014 (LH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>91A2F7CA-E7D4-42A5-BC32-5BAE58FE14BE</gtr:id><gtr:impact>Wider dissemination of work

None</gtr:impact><gtr:outcomeId>545cc26dc1c772.59791816</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop, Nuffield Council on Bioethics 2014 (BY)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B3DE11FC-F490-4BF9-96C9-44D3E65942BD</gtr:id><gtr:impact>Discussion of wide range of ethical, methodological, PPI and practical issues related to children's research worldwide

Nuffield Council report due April 2015</gtr:impact><gtr:outcomeId>545b519aa7f273.46197930</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Birmimgham 2013 RKD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C64C668C-7AB5-4D7B-B345-E53412EC4337</gtr:id><gtr:impact>150 participants. The talk was followed by a lively discussion.

Several participants approached to discuss their projects involving longitudinal biomarker data.</gtr:impact><gtr:outcomeId>MBQJVPu23Wi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Southampton 2012 DM</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>13F25C2E-804F-457A-BFBF-BC7F4D313AA1</gtr:id><gtr:impact>The talk contained some mathematical results concerning simultaneous confidence intervals for a multidimensional parameter, e.g., the treatment effect sizes in a multi-arm clinical study

New methodology for analyzing clinical trials involving multiple comparisons</gtr:impact><gtr:outcomeId>nygPL4RELdX</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 5th Annual Summit for Clinical Ops Executives 2014 (AHM)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>797EE99B-1B49-4930-B89E-44CB12B81756</gtr:id><gtr:impact>Dicussion

No notable impacts</gtr:impact><gtr:outcomeId>54588d324cce58.82933895</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DIRUM workshop 2011</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CF862D7E-8F9C-45C7-A2C5-1963E92686B9</gtr:id><gtr:impact>On 19th October 2011 a workshop was held in Birmingham where 40 people, mostly academic, contributed to discussions on methods for the collection of resource use data.

Group and panel discussions resulted in a short listing of priority areas for defining a research agenda.</gtr:impact><gtr:outcomeId>qeXsHgEBFiA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>International Clinical Trials Day 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6549B668-E7B4-4F96-A57B-6140E1EBC181</gtr:id><gtr:impact>Invited to speak about the COMET Initiative as part of the European Clinical Research Infrastructure Network's 2012 International Clinical Trials' Day Celebration in Dublin on 18th May 2012 http://www.ecrin.org/index.php?id=34

Participants at the meeting asked for details of the next meeting of the COMET Initiative.</gtr:impact><gtr:outcomeId>ZZZBGRL5fmp</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RSS meeting 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6E912E9F-1B78-4055-9C3B-977B350D9C8A</gtr:id><gtr:impact>Approx 50 people from a range of institutions attended a talk on a joint modelling approach to determine the predictive accuracy of a longitudinal biomarker. The talk was followed by a lively discussion where participants discussed applying the methods in their clinical data/settings

Participants requested the software JoineR</gtr:impact><gtr:outcomeId>qRe9Xy5vjRJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Symposium on Early Phase Dose Finding Methodology 2015 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E940E22F-C959-4BF6-A92E-419140665045</gtr:id><gtr:impact>Raising profile of Hub; Dissemination of hub research


NA</gtr:impact><gtr:outcomeId>567a667dd7afb0.17168916</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop, Liverpool 2012 CTS</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8B8FD28F-07C0-4D58-A92E-97C94485BEDB</gtr:id><gtr:impact>50 delegates with 34 registered CTUs, 6 hubs and the MHRA represented attended a workshop on monitoring in Liverpool.

As a result of the workshop an invitation was received to present a workshop at the Trial Managers Network conference. Since the workshop we have received a request for one of the CTUs to visit the Clinical Trials Research Centre to discuss monitoring practice further. Another CTU has requested further information about developing central statistical monitoring methods. A further CTU has requested information on the risk assessment approach used at CTRC. Another CTU has visited the CTRC to discuss monitoring approaches.</gtr:impact><gtr:outcomeId>Z2d77gxfL8s</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PACT workshop, Manchester 2014 (PB)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>86D3C329-E691-4C26-A9C2-5FC65E986101</gtr:id><gtr:impact>20 participants knowledge exchange and identification of future methodological research to improve patient experience of trials

Links with INVOLVE</gtr:impact><gtr:outcomeId>545741f284d731.07468769</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET talk, InFACT/ISF Outcome Measures Colloquium, Amsterdam, 2013 (PW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F24146B2-E4F0-4F75-BB56-75BB476C8868</gtr:id><gtr:impact>Talk delivered and active participation in workshop.

Ongoing collaboration.</gtr:impact><gtr:outcomeId>eryR1WN1vkd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Heidelberg 2012 DM</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F3C15DC0-59ED-4CD4-8CAD-6171A9C99E5F</gtr:id><gtr:impact>The talk contained some mathematical results concerning simultaneous confidence intervals for a multidimensional parameter, e.g., the treatment effect sizes in a multi-arm clinical study

New methodology for analyzing clinical trials involving multiple comparisons</gtr:impact><gtr:outcomeId>AsiHNynV84a</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET talk, PSI Annual conference, Glasgow, 2013 (PW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>027A8503-3C76-4B2B-8EF8-D1C767C68A2D</gtr:id><gtr:impact>Delivered to wider audience.

Talk well received, audience participation and questions. Advice provided.</gtr:impact><gtr:outcomeId>ro9pQJUDDWD</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, UK 2013 TJ</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>76DB5222-951A-408E-AC71-16C35E859CE3</gtr:id><gtr:impact>It has allowed wider dissemination of the work

Some specific queries about implementing our methods</gtr:impact><gtr:outcomeId>hPBUcX8ZsAJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Workshop, Canada 2012 BY</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D9896BC3-EDC3-426A-A860-F67BFF3DB782</gtr:id><gtr:impact>Identification of key points of difference in models and areas for future research

Lead to an idea for a paper, which has been drafted (by a workshop participant) and is expected to be submitted soon</gtr:impact><gtr:outcomeId>SYYrXCNuGaF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, SMi Conference on Adaptive designs in Clinical Trials 2014 (LH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E21CF4C3-1A9D-47C7-AE21-DBD1FF873ED1</gtr:id><gtr:impact>Wider dissemination of work to the pharmaceutical industry

None</gtr:impact><gtr:outcomeId>545cc1734cadb8.21813402</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, 36th Society for Clinical Trials Conference 2015 (TJ)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0B3E33C3-A626-42F2-A8CD-F286CC390655</gtr:id><gtr:impact>Raising profile of Hub; Dissemination of hub research


NA</gtr:impact><gtr:outcomeId>567a6631c426e7.27104844</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Novartis internal statistics seminar series 2014 (SS)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>98653B32-1924-4C08-B27D-537BEB8CE163</gtr:id><gtr:impact>Wider dissemination of work


None</gtr:impact><gtr:outcomeId>545cc3005cefb2.47821930</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Local COMET meeting 2012</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>342EB222-AA69-4369-8CD9-AC2C5111E480</gtr:id><gtr:impact>A meeting was held in Liverpool on 17th January 2012 for those with interest in core outcome sets development projects that are being led from Liverpool. Individuals discussed their projects and shared their expertise and ideas.

Some important methodological considerations were raised, including the necessity to define the scope of each core outcome set as each will be unique, the importance of the questions you ask to patients and clinicians and the differences in methods being used.</gtr:impact><gtr:outcomeId>pKmACX9Fwk4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Barcelona Biomed 2012 LH</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2084628-7737-4BC2-ABA0-0F9D4E9EF193</gtr:id><gtr:impact>Communicated research to broad audience of statisticians and received useful feedback from the audience

Not measurable yet</gtr:impact><gtr:outcomeId>Cs39DaqodLc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Institute Gustave-Roussy 2014 (LH)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B6AF3C55-7B64-400B-91B8-C3712D768E3A</gtr:id><gtr:impact>Wider dissemination of work

Developed a collaboration with Dr Marie-Cecile Le Deley which has culminated in joint supervision of a PhD student who started in October 2014 and is developing novel Bayesian designs for clinical trials in rare cancers</gtr:impact><gtr:outcomeId>545cc1f497ab16.87248565</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, London 2012 JW</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0E4C5C50-EC68-4FDC-989C-B4CA512F1BB3</gtr:id><gtr:impact>The talk presented early ideas on eliciting opinion which, after refinement and improvement, has led to the methodology implemented for the MYPAN trial

The meeting led to exchange of ideas and promotion of the Bayesian approach. There has been subsequent interest in using the methodology, but attribution to any particular meeting is difficult.</gtr:impact><gtr:outcomeId>oYNCuGf3Zgd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Manchester 2012 BY</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A76EFDEC-1F6B-49F8-9790-A04D89DD218B</gtr:id><gtr:impact>Practitioners are concerned about the burden posed to families by inviting children to participate in clinical trials but families report that they are happy to be approached about clinical trials

Not known</gtr:impact><gtr:outcomeId>evBAtWYoTua</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Manchester 2014 (PB)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>31E07EEB-4E01-4E60-B856-E6D5448D396F</gtr:id><gtr:impact>Education and training

Change in practice in attendants</gtr:impact><gtr:outcomeId>5457433a2de6f4.62624895</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Norway 2012 KP</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5922E4B7-C844-44D1-AF14-F5FCE9A7B05D</gtr:id><gtr:impact>This was an international talk where the audience were International Biostatisticians from both academia and industry

The talk was well received and some connections were made with industry professionals who offered advice about practical considerations</gtr:impact><gtr:outcomeId>pisGCSruvA2</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Heidelberg 2012 LH</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>891581B5-AA96-49AD-8370-BD91D40E2F04</gtr:id><gtr:impact>Communicated research to a wider audience

Not yet measurable</gtr:impact><gtr:outcomeId>TZZHhzzYhqE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Newcastle 2012 TJ</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8E76C00B-8152-41CD-B219-DBCF09DC85AA</gtr:id><gtr:impact>It has allowed wider dissemination of the work

None known of</gtr:impact><gtr:outcomeId>pu5Ai56JPRd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Oslo 2012 TJ</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DE7F7571-512F-40AE-B2D3-7F47D3A0B12D</gtr:id><gtr:impact>It has allowed wider dissemination of the work

Some discussions on using our methods in different studies</gtr:impact><gtr:outcomeId>QbE3yMNNXD7</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, EMA 2012 LH</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3FCAD348-169C-4228-B91A-82950F8BD70F</gtr:id><gtr:impact>Communicated research findings to PDCO and obtained their feedback on project

Not measurable yet</gtr:impact><gtr:outcomeId>GSM9DsKifTo</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET talk, EQUATOR 2012 PW</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>396BB580-081A-4B55-8E5E-D63C65CAF4F2</gtr:id><gtr:impact>The aims and progress of the COMET Initiative were described

The talk raised awareness amongst international clinical research groups</gtr:impact><gtr:outcomeId>fpWCCY55JkP</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Wales 2012 DH</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>CBF6DCFC-34C3-47A9-A919-09453F4F288A</gtr:id><gtr:impact>The presentation concerned the cost-effectiveness of dabigatran, rivaroxaban, apixaban and warfarin for the management of patients with atrial fibrillation

The research informed the development of the advice in Wales on the role of the new oral anticoagulants, and was submitted for consideration by NICE, of the cost-effectiveness of dabigatran</gtr:impact><gtr:outcomeId>QWePQY4tbFg</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Tokyo 2012 DH</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>56A1BC1D-7F14-4D6D-A00E-7AFBA97A0555</gtr:id><gtr:impact>The presentation included an overview of the methods of health technology assessment of novel genetic predictors of drug response.

The intention was to stimulate UK/Japan collaborative research in the area of personalised medicine</gtr:impact><gtr:outcomeId>MnGQ7ZpETcM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit to Vienna 2011</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0598A163-155E-419B-9442-84A4478141EE</gtr:id><gtr:impact>A visit was made to the Medical University in Vienna to work with experts in the field of adaptive designs.

Many opportunities for collaborations and joint work were identified and the first joint project is nearing its finalisation.</gtr:impact><gtr:outcomeId>YET8hF6qYwb</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET talk, 2nd UK Clinical Trials Methodology Conference, Edinburgh, 2013 (LG)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>553B6569-7E9A-493F-9996-CC3521DF0977</gtr:id><gtr:impact>Abstract accepted to present systematic review

Not known yet.</gtr:impact><gtr:outcomeId>tubXCLBoc3g</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Cambridge 2012 LH</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8FCC0A13-CA03-464E-B047-B377016D937E</gtr:id><gtr:impact>Communicated research to a wider audience

Subsequently approached to share presentation slides with members of audience</gtr:impact><gtr:outcomeId>U1D2HsADN6C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Grand Round 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>91C4C863-E4F9-4AFE-8953-851FFC16583E</gtr:id><gtr:impact>Presented findings from RECRUIT on parents' and practitioners' perspectives on recruitment to children's clinical trials at Alder Hey Children's Hospital, May 2011.

Discussions following presentation led to funding application</gtr:impact><gtr:outcomeId>VzkWrr1APtJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>COMET workshop, 21st Cochrane Colloquium, Canada, 2013 (PW)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>59EE6041-5EFE-4C09-9BAD-DD1A8C2B7CB5</gtr:id><gtr:impact>Interactive workshop delivered, attended by 25 individuals.

Feedback sought from systematic reviewers about suitability of workshop for this audience.</gtr:impact><gtr:outcomeId>hYNcGbB7zhU</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, Liverpool 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>10781CA4-EF38-4904-A613-4B62FC1A478E</gtr:id><gtr:impact>Talk to a broad audience of basic researchers, clinicians, policy makers, industry and the public on a novel early phase trial design.

Novel early phase trial design is currently being implemented in a CRUK trial.</gtr:impact><gtr:outcomeId>TqLhSvm6uMi</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>169000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Post-doctoral Research Fellowship</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>095874/2/11/2</gtr:fundingRef><gtr:id>E4B98406-B5BB-4751-A54D-EB68B1228BEC</gtr:id><gtr:outcomeId>RULgzcemGJv</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>7000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R46</gtr:description><gtr:end>2014-11-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R46</gtr:fundingRef><gtr:id>4BAA1388-DE5F-4983-895B-18AADDFB0474</gtr:id><gtr:outcomeId>5457442c108ca8.87051753</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Butterfield Awards for UK-Japan Collaboration in Medicine and Health</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>The Great Britain Sasakawa Foundation</gtr:fundingOrg><gtr:id>5EF8C24A-7434-454C-93C3-834233FC783D</gtr:id><gtr:outcomeId>VP3rud3YBWM</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R1</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R1</gtr:fundingRef><gtr:id>B34ACFE1-609E-4C8A-ADD0-7348C9D74440</gtr:id><gtr:outcomeId>r244BYdXJHg0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>497368</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Framework Programme 7</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>67F47BC9-08BE-4C19-897D-E6C81E9C6A36</gtr:id><gtr:outcomeId>qjY67VS4L3i</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>280000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>CHF</gtr:currCode><gtr:currCountryCode>Switzerland</gtr:currCountryCode><gtr:currLang>it_CH</gtr:currLang><gtr:department>Roche Diagnostics</gtr:department><gtr:description>Research Fellowship Programme</gtr:description><gtr:fundingOrg>F. Hoffmann-La Roche AG</gtr:fundingOrg><gtr:id>28358778-B7FE-4F75-A65F-C69C9CF00A8C</gtr:id><gtr:outcomeId>TpHnW8E3cnU</gtr:outcomeId><gtr:sector>Private</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>46220</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R18</gtr:description><gtr:end>2013-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R18</gtr:fundingRef><gtr:id>044EB8B5-24F4-446E-85AD-F458DB9B20C6</gtr:id><gtr:outcomeId>MMuDUy22vtZ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12941</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R7</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R7</gtr:fundingRef><gtr:id>2DF094C8-35C6-49D8-B659-8A3F04DBEA4E</gtr:id><gtr:outcomeId>LH3gASjXHkp0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>3761CC03-E6ED-4B5F-837F-C569A6EDB6C4</gtr:id><gtr:outcomeId>Pr5ph1wTcov0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Methods Fellowship</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>MET-2012-12-27</gtr:fundingRef><gtr:id>31783CD3-1B4B-45FE-8196-AD50805D388E</gtr:id><gtr:outcomeId>Xtvm5DG4K2t</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>549000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Methodology Research Panel</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>1E53BEA0-884B-4F0E-9AE0-651306BBCE70</gtr:id><gtr:outcomeId>L2Dt2XpPCS4</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>36314</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R19</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R19</gtr:fundingRef><gtr:id>CB781D25-7AB6-4C46-AFA2-7967D0D0745C</gtr:id><gtr:outcomeId>gzAQ5VjPvDt</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>1B47FEA0-C4EE-445C-A06E-9C7D945E97A9</gtr:id><gtr:outcomeId>NvsJY2u8rVE0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>480000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Cochrane Programme Grant</gtr:description><gtr:end>2014-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>4FCBEBC2-75AE-4D2C-B6B7-66493AAB7941</gtr:id><gtr:outcomeId>PZUMEshTVhi0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2300</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R13</gtr:description><gtr:end>2011-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R13</gtr:fundingRef><gtr:id>ADEB06A4-BFC5-47FF-9D94-470E012DC033</gtr:id><gtr:outcomeId>J67ygikDLCM</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15712</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R14</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R14</gtr:fundingRef><gtr:id>CE825BA4-A596-422A-B255-DD6DF103384D</gtr:id><gtr:outcomeId>crXHubgwDVA0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>173273</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Methodology Research Panel</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J004847/1</gtr:fundingRef><gtr:id>5CD6997A-5C38-44C7-B89B-875DD607F9F8</gtr:id><gtr:outcomeId>r5nNtg4UHPZ</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>42251</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>School for Primary Care Research Capacity</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>B4331B00-208B-4D20-A8DE-13FB99A35180</gtr:id><gtr:outcomeId>54574509952489.89839085</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Methods Fellowship</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>F6578BBF-F899-499A-AE2E-6E9CE6A1E695</gtr:id><gtr:outcomeId>dkYi7t9GPZZ</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>RMOFS 2012/09</gtr:fundingRef><gtr:id>841EBD40-9016-4A9D-A75D-8D388470F3F1</gtr:id><gtr:outcomeId>qiWzogFd4Y1</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Research for Patient Benefit</gtr:department><gtr:description>The Research for Patient Benefit Programme</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>14A2A936-3B32-4053-967C-004F64B568A1</gtr:id><gtr:outcomeId>fGxskbk1H2D0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>49082</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R30</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R30</gtr:fundingRef><gtr:id>39976498-4C99-467E-9E6D-B4DDA363D980</gtr:id><gtr:outcomeId>WqYLrt1Zjxc</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1536010</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR HTA</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>12/127</gtr:fundingRef><gtr:id>0C171F87-0D83-447E-AD87-7D7945C6F446</gtr:id><gtr:outcomeId>545b5369964dc7.98416589</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>91000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Methods Fellowship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>MET-2012-18</gtr:fundingRef><gtr:id>4A118B34-717D-4A72-95D3-84DADBFBC9AC</gtr:id><gtr:outcomeId>BkTA2zXpSiD</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>16052</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R24</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R24</gtr:fundingRef><gtr:id>F80F1BBB-F856-4692-BD9F-930FAB204AB7</gtr:id><gtr:outcomeId>S75fqMkfJDu</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>685814</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Methodology Panel Award</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>G0902155</gtr:fundingRef><gtr:id>EFAA31C9-5B84-494C-8214-3ED91DB1CF7E</gtr:id><gtr:outcomeId>LdDXwQP8AtP0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>32523</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R5</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R5</gtr:fundingRef><gtr:id>D2F3CEE9-9A82-45EE-B7C7-FFDAEE03D50B</gtr:id><gtr:outcomeId>brT4XG1KDzs0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>12721</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Network of Hubs for Trials Methodology Research R31</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>R31</gtr:fundingRef><gtr:id>9DCBC815-5B05-4FA4-8146-AB095C7D2456</gtr:id><gtr:outcomeId>MhWiJeSyCY2</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>301658</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Career Development Fellowship</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>5DAE993D-FDCF-477B-BA5F-A7C722320047</gtr:id><gtr:outcomeId>YyTm13HWRR20</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>625000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/ARUK Musculoskeletal Ageing Centre (Liverpool/Sheffield/Newcastle)</gtr:description><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>DBB070BF-4FFA-4D8B-835F-C5E49DCE361C</gtr:id><gtr:outcomeId>HL4UR6y2bUY1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1875000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC/ARUK Musculoskeletal Ageing Centre (Liverpool/Sheffield/Newcastle)</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>35AC8DC1-527C-4EC8-91B8-EE9868197216</gtr:id><gtr:outcomeId>HL4UR6y2bUY0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>SPIRIT 2013 guidance for protocols of clinical trials now includes reference to COMET</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A0ACE695-A212-4F20-8843-740F38C6EB10</gtr:id><gtr:outcomeId>MPC5vJMosQY</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Implications for driving</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9A15C2BF-4E33-4D4F-88C4-BC898EDED5EB</gtr:id><gtr:impact>Providing evidence to coincide with currently recognised UK guidance on driving for patients with epilepsy. From this a change in policy has resulted in the UK and it is planned to use this analysis to harmonise EU and UK driving regulations. This work is not directly related to trials methodology but this demonstrates added value since work benefited from methods applied to analysis of trials data.</gtr:impact><gtr:outcomeId>fn4pAtiFGvD</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Impact of outcome reporting bias</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>D46BCDEA-B017-4ECA-AC0B-DEE9188A83B9</gtr:id><gtr:outcomeId>6040712B5EF</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in clinical guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>NICE Guideline</gtr:guidelineTitle><gtr:id>322BF066-B13B-49D8-9F07-B350735CB311</gtr:id><gtr:outcomeId>UMBspTEwNQe</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>HTA outline proposal form now includes reference to COMET</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A1FBFF40-D402-44E6-8726-5734FEF693AB</gtr:id><gtr:outcomeId>f5VNK7Bd8NE</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Paediatric asthma COS/COMET: response to EMA</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>037CBB7B-EA7A-4057-8585-367F771702AB</gtr:id><gtr:outcomeId>fEJZ3FvupbG</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>An assessment of the impact of outcome reporting bias in randomised controlled trials within systematic trials</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>8D14796C-5EC9-4886-BEA0-1B610C4346B8</gtr:id><gtr:outcomeId>g7kwdM6JB5t</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Methods referred to in Cochrane handbook</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>48EB32A8-6680-4765-8F42-6CBD501B81DC</gtr:id><gtr:outcomeId>C511AE5C0CC</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Shareware software to implement methods developed.</gtr:description><gtr:id>FCE666D7-7D5A-418F-9BA4-E6409D8DA5A6</gtr:id><gtr:impact>Request for access from researchers.</gtr:impact><gtr:outcomeId>9817405E033</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Statistical software</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The COMET website hosts a searchable database. The website is currently live. The website was developed using funding awarded by the MRC Network of Hubs for Trials Methodology Research.</gtr:description><gtr:id>78DB30C9-05A7-4F2D-984D-333254C1EE25</gtr:id><gtr:impact>From its launch in August 2011 to date the website has had 14,874 database searches and 53,749 unique visitors from 174 countries.</gtr:impact><gtr:outcomeId>mQ9xiQyjg6e</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>COMET Website</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:url>http://www.comet-initiative.org/</gtr:url><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>The DIRUM (Database of Instruments for Resource Use Measurement) website provides a practical, open-access database of resource-use questionnaires for use by trial health economists. The website is currently live. The website received funding from the MRC Network of Hubs for Trials Methodology Research.</gtr:description><gtr:id>B4D1A08F-2D8E-4814-B5F6-D6F64A1213DC</gtr:id><gtr:impact>Since its launch on 6 June 2011 to 14 November 2011 the website has had 1971 visits and 440 downloads.</gtr:impact><gtr:outcomeId>T6iNxMh8o4u</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>DIRUM website</gtr:title><gtr:type>Support Tool - For Fundamental Research</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Outcome reporting bias is an under-recognised problem which can affect the inference in a systematic review. Reviewers should address explicitly the issue of missing outcome data in order for reviews to be considered a reliable source of evidence about healthcare practice. We have proposed an outcome matrix be used for this purpose alongside the development of a new classification system for the assessment of selective outcome reporting.</gtr:description><gtr:id>0372F6F0-E37C-4690-AFA2-D8A508B00986</gtr:id><gtr:impact>The main findings were that a third of Cochrane reviews contained at least one trial with high outcome reporting bias (ORB) suspicion for the review primary outcome. Considering meta-analyses with a statistically significant result only, just under a fifth were not robust to ORB and over a quarter would have overestimated the treatment effect by 20% or more. We found ORB to be an under-recognised problem which affects the inference in a substantial proportion of Cochrane reviews.</gtr:impact><gtr:outcomeId>A2EZgjzYCA6</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>ORBIT</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Novel methods for joint modelling combined repeated measurements and event-time data, or informative drop-out were developed and published. These methods were exploited fully in substantive applications over a range of medical settings including epilepsy treatment, cardio-thoracic surgery and renal medicine. Software for the new methods was developed as an add-on package (&amp;quot;JoineR&amp;quot;) within the R environment so as to make the software freely available to researchers.</gtr:description><gtr:id>FA5789BA-0B7C-465C-A1A6-6457E68C49B3</gtr:id><gtr:impact>Joint modelling approach provided the clinical research community with an awareness of the potential problems commonly occur in clinical and observational studies and the inefficiency of use of simple statistical methods which are often failing to take account of informative dropout during the intended follow-up period. Thereby we have improved current practice in the analysis of the complex longitudinal data structures that commonly arise in clinical and public health research.</gtr:impact><gtr:outcomeId>TovpYESPFFX</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Joiner</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AA77D975-AD29-44BF-A86C-D428B1EB00D1</gtr:id><gtr:title>A multivariate meta-analysis approach for reducing the impact of outcome reporting bias in systematic reviews.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17f519190d217d4e666d854dbdf4787"><gtr:id>a17f519190d217d4e666d854dbdf4787</gtr:id><gtr:otherNames>Kirkham JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13169_29_22532016</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8A7E7E8-6715-4BB8-A6C5-E395D06E7F40</gtr:id><gtr:title>Uptake of novel statistical methods for early-phase clinical studies in the UK public sector.</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>pm_13169_29_23378484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50D9C163-47EB-40EA-9FB3-FA97BD52FCD5</gtr:id><gtr:title>Estimation of the warfarin dose with clinical and pharmacogenetic data.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9ff78804b255afb737a51ad71fdbc0f9"><gtr:id>9ff78804b255afb737a51ad71fdbc0f9</gtr:id><gtr:otherNames>International Warfarin Pharmacogenetics Consortium</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>3655E70CDC4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D747D8B-94C1-4874-8947-77D665477674</gtr:id><gtr:title>Investigating the assumption of homogeneity of treatment effects in clinical studies with application to meta-analysis.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b617dca47e5e8685e4d07f0194364adb"><gtr:id>b617dca47e5e8685e4d07f0194364adb</gtr:id><gtr:otherNames>Julious SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>pm_13169_29_22140032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3AE3CD6C-7A71-4C1C-94FB-468AC792B0DF</gtr:id><gtr:title>A hybrid method to estimate the minimum effective dose for monotone and non-monotone dose-response relationships.</gtr:title><gtr:parentPublicationTitle>Biometrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0116550b3dfcd7c4b2f420753b124c5"><gtr:id>a0116550b3dfcd7c4b2f420753b124c5</gtr:id><gtr:otherNames>Wolfsegger MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-341X</gtr:issn><gtr:outcomeId>545353d425e1b7.79856693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA8F04D6-28AD-4568-8933-456D9317A1C5</gtr:id><gtr:title>Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b37ca4a49d0616af26ea31242e516956"><gtr:id>b37ca4a49d0616af26ea31242e516956</gtr:id><gtr:otherNames>Pink J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>kniyc4WEgdQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A065AA5-04FD-4B94-A018-C2F9DC05BE12</gtr:id><gtr:title>Pharmacogenetic tests: the need for a level playing field.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7f5e520a9ef4577b5eb75515fa5bb39"><gtr:id>e7f5e520a9ef4577b5eb75515fa5bb39</gtr:id><gtr:otherNames>Pirmohamed M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>pm_13169_29_23274456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69B03CFE-5A85-456A-97FF-5F717581E1FB</gtr:id><gtr:title>Barriers to recruiting ethnic minorities to mental health research: a systematic review.</gtr:title><gtr:parentPublicationTitle>International journal of methods in psychiatric research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26abd53b6933c80866a7eb492ea6efa6"><gtr:id>26abd53b6933c80866a7eb492ea6efa6</gtr:id><gtr:otherNames>Brown G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1049-8931</gtr:issn><gtr:outcomeId>54573ef8a5b475.80661245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0115FB50-9498-4DBD-852F-11FD7BB808FF</gtr:id><gtr:title>Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs.</gtr:title><gtr:parentPublicationTitle>Journal of pharmacokinetics and pharmacodynamics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0116550b3dfcd7c4b2f420753b124c5"><gtr:id>a0116550b3dfcd7c4b2f420753b124c5</gtr:id><gtr:otherNames>Wolfsegger MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1567-567X</gtr:issn><gtr:outcomeId>DDAFF55B821</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C4A476F-158E-4A68-BF38-9312B310E6D1</gtr:id><gtr:title>Sharing individual participant data from clinical trials: an opinion survey regarding the establishment of a central repository.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_540e15fe15f2604d7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C8A8A530-16E9-4823-BA2C-0FA9C5A73D84</gtr:id><gtr:title>A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13169_29_22495759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E740D0CC-05F9-4979-AF8A-EFC3A00FD9DB</gtr:id><gtr:title>Using the Delphi technique to determine which outcomes to measure in clinical trials: recommendations for the future based on a systematic review of existing studies.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe5f56f8960ed3ede9d724858b2d06d"><gtr:id>cbe5f56f8960ed3ede9d724858b2d06d</gtr:id><gtr:otherNames>Sinha IP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>gV9Tk7kWnEd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FA7D83D-7748-41E0-B475-D834B493E559</gtr:id><gtr:title>Resource-use measurement based on patient recall: issues and challenges for economic evaluation.</gtr:title><gtr:parentPublicationTitle>Applied health economics and health policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f9c56de6e4545472969f47308ff1793"><gtr:id>4f9c56de6e4545472969f47308ff1793</gtr:id><gtr:otherNames>Thorn JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1175-5652</gtr:issn><gtr:outcomeId>pm_13169_29_23529715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34002FA7-848A-4318-83E5-497D2326F859</gtr:id><gtr:title>Development of a core outcome set for clinical trials in childhood asthma: a survey of clinicians, parents, and young people.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe5f56f8960ed3ede9d724858b2d06d"><gtr:id>cbe5f56f8960ed3ede9d724858b2d06d</gtr:id><gtr:otherNames>Sinha IP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13169_29_22747787</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4A24749-65F5-4F58-B0A7-00F208AD3309</gtr:id><gtr:title>Doing challenging research studies in a patient-centred way: a qualitative study to inform a randomised controlled trial in the paediatric emergency care setting.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef216dd99d26d1b38c076799060e74b1"><gtr:id>ef216dd99d26d1b38c076799060e74b1</gtr:id><gtr:otherNames>Woolfall K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>545355f0cf7a30.65143058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5212B818-92CC-4CD2-B7C4-7766D849D87A</gtr:id><gtr:title>Some recommendations for multi-arm multi-stage trials.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/667b3a7c3073fc54ec79ec58d0024d3b"><gtr:id>667b3a7c3073fc54ec79ec58d0024d3b</gtr:id><gtr:otherNames>Wason J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>pm_13169_29_23242385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C64650C4-DBA2-426B-96DE-3FA84DED6AE0</gtr:id><gtr:title>Patient and public participation in health care: can we do it better?</gtr:title><gtr:parentPublicationTitle>The American journal of bioethics : AJOB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c5670d6555aab222e77b3ce1b03f7b7"><gtr:id>2c5670d6555aab222e77b3ce1b03f7b7</gtr:id><gtr:otherNames>Frith L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1526-5161</gtr:issn><gtr:outcomeId>545355f0f34a58.19500061</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D49D7157-6455-4B86-8F69-EF6A63E690ED</gtr:id><gtr:title>Patient and public involvement in the early stages of clinical trial development: a systematic cohort investigation.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d21017d656b537490aad9baf03f046fc"><gtr:id>d21017d656b537490aad9baf03f046fc</gtr:id><gtr:otherNames>Gamble C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>545355f12676a6.80849085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E389F208-16EE-46FA-9B97-7BB1FAD05B89</gtr:id><gtr:title>Planning multi-arm screening studies within the context of a drug development program.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13169_29_23529936</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DFAAF66-EA1C-4EE2-8671-E95919A31E7C</gtr:id><gtr:title>Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4c17dbb2e8f258a40264a36693cbc0c"><gtr:id>c4c17dbb2e8f258a40264a36693cbc0c</gtr:id><gtr:otherNames>Linley WG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>pm_13169_29_22676385</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29D83D9D-5A96-4C28-A02E-BD5CA7E1BC03</gtr:id><gtr:title>Exercise and self-management for people with chronic knee, hip or lower back pain: a cluster randomised controlled trial of clinical and cost-effectiveness. Study protocol.</gtr:title><gtr:parentPublicationTitle>Physiotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d0648e51e0fc044cd86137c622e8c73"><gtr:id>0d0648e51e0fc044cd86137c622e8c73</gtr:id><gtr:otherNames>Walsh N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0031-9406</gtr:issn><gtr:outcomeId>pm_13169_29_23200601</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2159D7FF-7732-4430-9221-09D72818C4E2</gtr:id><gtr:title>Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b37ca4a49d0616af26ea31242e516956"><gtr:id>b37ca4a49d0616af26ea31242e516956</gtr:id><gtr:otherNames>Pink J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_540e15ee15ef9761c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CBC5F9DF-C8E6-44CF-9708-2B48B6DBC59A</gtr:id><gtr:title>Estimating drug costs in economic evaluations in Ireland and the UK: an analysis of practice and research recommendations.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3b59c01318db7c233a9f9e667e937a"><gtr:id>4f3b59c01318db7c233a9f9e667e937a</gtr:id><gtr:otherNames>Hughes DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>C76F6DC5543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1A7E14BD-849B-4EBB-A9B4-D85CDAB1C5E1</gtr:id><gtr:title>Opening research sites in multicentre clinical trials within the UK: a detailed analysis of delays.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a60ca4562193248cecd9df322b5f60d"><gtr:id>6a60ca4562193248cecd9df322b5f60d</gtr:id><gtr:otherNames>Kearney A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>doi_55f984984c07a6cd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF6563CC-2A3E-4A55-B0A7-CE5239664717</gtr:id><gtr:title>Biosimilars: evidential standards for health technology assessment.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3b59c01318db7c233a9f9e667e937a"><gtr:id>4f3b59c01318db7c233a9f9e667e937a</gtr:id><gtr:otherNames>Hughes DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>FD632B32DB7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CB32097-EB9A-4C06-96BF-187922777311</gtr:id><gtr:title>A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7fb930e5ff47e57d0da5d3a60f9ad42f"><gtr:id>7fb930e5ff47e57d0da5d3a60f9ad42f</gtr:id><gtr:otherNames>Guzauskas GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_13169_29_22453194</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BEE9AD3-832E-4B72-B6E8-2318623BD567</gtr:id><gtr:title>Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03db2458b85a51d20f3a242bb7b7fd4b"><gtr:id>03db2458b85a51d20f3a242bb7b7fd4b</gtr:id><gtr:otherNames>Hughes D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>585d5427cb68b7.97536564</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>721F0B41-BDB4-4CEF-935A-1658380FB748</gtr:id><gtr:title>The role of systematic reviews in pharmacovigilance planning and Clinical Trials Authorisation application: example from the SLEEPS trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d21017d656b537490aad9baf03f046fc"><gtr:id>d21017d656b537490aad9baf03f046fc</gtr:id><gtr:otherNames>Gamble C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>QsYQCwSiiYU</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E79DF74-EA62-4C8B-A9C2-9E00ACE50D33</gtr:id><gtr:title>Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b37ca4a49d0616af26ea31242e516956"><gtr:id>b37ca4a49d0616af26ea31242e516956</gtr:id><gtr:otherNames>Pink J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>pm_13169_29_22428718</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDC64F5A-D46A-40FC-AA39-E7DEA6F60C61</gtr:id><gtr:title>Associates of stigma in an incident epilepsy population from northern Manhattan, New York City.</gtr:title><gtr:parentPublicationTitle>Epilepsy &amp; behavior : E&amp;B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16b8620866ed76f3598bda34379dcccb"><gtr:id>16b8620866ed76f3598bda34379dcccb</gtr:id><gtr:otherNames>Leaffer EB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-5050</gtr:issn><gtr:outcomeId>pm_13169_29_21482485</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F436A2A0-5725-45FB-89C9-9F82C927900C</gtr:id><gtr:title>The development of a QALY measure for epilepsy: NEWQOL-6D.</gtr:title><gtr:parentPublicationTitle>Epilepsy &amp; behavior : E&amp;B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0dd2420decff59b0397c17fb9571fdb"><gtr:id>e0dd2420decff59b0397c17fb9571fdb</gtr:id><gtr:otherNames>Mulhern B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-5050</gtr:issn><gtr:outcomeId>pm_13169_29_22503427</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F96E5CB-A5E7-41CA-B3B7-6166BBA8EF20</gtr:id><gtr:title>Statistical approaches for the determination of cut points in anti-drug antibody bioassays.</gtr:title><gtr:parentPublicationTitle>Journal of immunological methods</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/275c71660a57360bf8ed9cfe025ce293"><gtr:id>275c71660a57360bf8ed9cfe025ce293</gtr:id><gtr:otherNames>Schaarschmidt F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1759</gtr:issn><gtr:outcomeId>5672d1ac389dc5.51672671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B710B462-B8CD-42D7-9ADB-A96D57B67D03</gtr:id><gtr:title>The Importance of Integration of Stakeholder Views in Core Outcome Set Development: Otitis Media with Effusion in Children with Cleft Palate.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/563710b15a31a4a26184221dac7791dd"><gtr:id>563710b15a31a4a26184221dac7791dd</gtr:id><gtr:otherNames>Harman NL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5675e76a83cd2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D60BB458-4B35-45DF-9C52-9787011FAEF8</gtr:id><gtr:title>Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/929c01fad63b4752722556c629106f10"><gtr:id>929c01fad63b4752722556c629106f10</gtr:id><gtr:otherNames>Cotterill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5672d0da2a8c47.08246292</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2452EA93-E4BC-4258-8516-0B209EE986A7</gtr:id><gtr:title>One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>A3F0D6F9CCA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFD3D9CD-9995-4C05-BE7B-24CD7AB03704</gtr:id><gtr:title>Establishing bioequivalence in complete and incomplete data designs using AUCs.</gtr:title><gtr:parentPublicationTitle>Journal of biopharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1054-3406</gtr:issn><gtr:outcomeId>DpLKV4HwuPu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E055072D-6600-4EBD-8AD5-049548329BA1</gtr:id><gtr:title>Principles of dose finding studies in cancer: a comparison of trial designs.</gtr:title><gtr:parentPublicationTitle>Cancer chemotherapy and pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0344-5704</gtr:issn><gtr:outcomeId>pm_13169_29_23299793</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18E42871-F667-46F2-A399-5A43FF8DF373</gtr:id><gtr:title>Developing a survey of barriers and facilitators to recruitment in randomized controlled trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9c73b502f81abc35638f4e65342b3e"><gtr:id>fb9c73b502f81abc35638f4e65342b3e</gtr:id><gtr:otherNames>Kaur G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>mERSwR14Fy8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09FE117A-4D0C-4D73-B4DE-D41C27254DEF</gtr:id><gtr:title>Pharmacogenetic testing prior to carbamazepine treatment of epilepsy: patients' and physicians' preferences for testing and service delivery.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1b2121f46ca70f5cebcc8714b61001c"><gtr:id>e1b2121f46ca70f5cebcc8714b61001c</gtr:id><gtr:otherNames>Powell G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>585d38fc2bc018.49712974</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E5706C52-EBD9-43FA-A3BD-7D05205C88AD</gtr:id><gtr:title>Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18398d2456b36d6a01c08bd2153a1f44"><gtr:id>18398d2456b36d6a01c08bd2153a1f44</gtr:id><gtr:otherNames>Sorensen SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>D8770C08719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF69A896-1299-41FC-8F28-EA8960BA8EC1</gtr:id><gtr:title>A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov.</gtr:title><gtr:parentPublicationTitle>Orphanet journal of rare diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f81791fca14ffb338ffb006948776344"><gtr:id>f81791fca14ffb338ffb006948776344</gtr:id><gtr:otherNames>Bell SA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1750-1172</gtr:issn><gtr:outcomeId>doi_55f984984c19e899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B6580BD-4D32-4A2F-8E20-BC26CE9A6F88</gtr:id><gtr:title>Value-based pricing: incentive for innovation or zero net benefit?</gtr:title><gtr:parentPublicationTitle>PharmacoEconomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3b59c01318db7c233a9f9e667e937a"><gtr:id>4f3b59c01318db7c233a9f9e667e937a</gtr:id><gtr:otherNames>Hughes DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1170-7690</gtr:issn><gtr:outcomeId>pEsbPRHUECY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D709459-2F06-4073-AC52-1A60EE5D3997</gtr:id><gtr:title>Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b37ca4a49d0616af26ea31242e516956"><gtr:id>b37ca4a49d0616af26ea31242e516956</gtr:id><gtr:otherNames>Pink J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>pm_540e15ee15eee94ad</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6E7858D-4D26-4D26-AA02-1D989C1565D8</gtr:id><gtr:title>Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5672d402377be1.51474804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B979AC3-8435-4012-A6FC-0ABA84675876</gtr:id><gtr:title>The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17f519190d217d4e666d854dbdf4787"><gtr:id>a17f519190d217d4e666d854dbdf4787</gtr:id><gtr:otherNames>Kirkham JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>bExYQAT8cXC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5434F396-C3CB-4947-8C12-A69BBE7D50DB</gtr:id><gtr:title>Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data</gtr:title><gtr:parentPublicationTitle>NEW ENGLAND JOURNAL OF MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b05beaceb841badb80facf0cdd5d5a9f"><gtr:id>b05beaceb841badb80facf0cdd5d5a9f</gtr:id><gtr:otherNames>Klein T. E.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5a361dc22a9b25.03636007</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EFC67DAE-D65C-4EC9-B354-493759A2D2AD</gtr:id><gtr:title>Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/21f668352004702303f2e8e0e2b26d93"><gtr:id>21f668352004702303f2e8e0e2b26d93</gtr:id><gtr:otherNames>Vale CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>56b0c90eb25534.48692063</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FEE45ECA-794F-44B4-8AE4-D625E2A6992D</gtr:id><gtr:title>A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/efa19c9257b71369097e0750721dae80"><gtr:id>efa19c9257b71369097e0750721dae80</gtr:id><gtr:otherNames>Thygesen H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>pm_13169_29_23011957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1586EB50-3B22-45AF-A3E1-8D1F0A51E28B</gtr:id><gtr:title>A Systematic Review of Patients' Perspectives on the Subcutaneous Route of Medication Administration.</gtr:title><gtr:parentPublicationTitle>The patient</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cbbf8edefdbc89ec594d06a4a1c7208"><gtr:id>5cbbf8edefdbc89ec594d06a4a1c7208</gtr:id><gtr:otherNames>Ridyard CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1178-1653</gtr:issn><gtr:outcomeId>585d678872acc2.51329034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05931360-1C57-431D-AF5A-14BB2EFC02BA</gtr:id><gtr:title>Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bd7807b7e314ccca158a271ae22f156"><gtr:id>6bd7807b7e314ccca158a271ae22f156</gtr:id><gtr:otherNames>Smyth RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>CnGR8RKuPN6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>408A97A0-C1F2-4BAA-A602-190D68F38114</gtr:id><gtr:title>Methodology of clinical trials for rare diseases.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical rheumatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1521-6942</gtr:issn><gtr:outcomeId>pm_540e15fe15f3ad4d0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2059617-D41C-422B-A716-A43EEA200FAA</gtr:id><gtr:title>Multiple imputation of multiple multi-item scales when a full imputation model is infeasible.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/251e8f80dc64f3415ad91ed03022c666"><gtr:id>251e8f80dc64f3415ad91ed03022c666</gtr:id><gtr:otherNames>Plumpton CO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>585d53c2af7742.82597937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31DC0C76-DB6C-4FB8-B83B-3AD9D6683110</gtr:id><gtr:title>Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5672d082639806.36129476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F040A7E0-0FB1-4711-898D-F8FFBA873DDF</gtr:id><gtr:title>Self-reported and parent-reported quality of life of children and adolescents with new-onset epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a209535e7da79b5d62367bda05695b6"><gtr:id>4a209535e7da79b5d62367bda05695b6</gtr:id><gtr:otherNames>Taylor J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>pm_13169_29_21569020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8896C3CF-92A1-4F11-84B9-0BF2DC276796</gtr:id><gtr:title>Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cbbf8edefdbc89ec594d06a4a1c7208"><gtr:id>5cbbf8edefdbc89ec594d06a4a1c7208</gtr:id><gtr:otherNames>Ridyard CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>rbyr71PeaGC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A487F4C1-7D07-4305-9B50-6BB67EF7FEEC</gtr:id><gtr:title>A new taxonomy for describing and defining adherence to medications.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68246123783d27d192bf97b646d9babd"><gtr:id>68246123783d27d192bf97b646d9babd</gtr:id><gtr:otherNames>Vrijens B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>pm_13169_29_22486599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28C80659-5A6C-42C1-B10C-8E8E26D8BEB2</gtr:id><gtr:title>Adaptive clinical trials in tuberculosis: applications, challenges and solutions.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fd0bd9d624f992d94fa7c0f219fb2903"><gtr:id>fd0bd9d624f992d94fa7c0f219fb2903</gtr:id><gtr:otherNames>Davies GR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn><gtr:outcomeId>5672d162ec47e5.59191832</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>208ADA33-8D71-4D29-B010-9DB7CCB9FC8F</gtr:id><gtr:title>Non-compartmental estimation of pharmacokinetic parameters for flexible sampling designs.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>SbdRiNL5X1L</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4F4E021-EFC0-4C81-B195-D479359AEE46</gtr:id><gtr:title>Assessing systemic drug exposure in repeated dose toxicity studies in the case of complete and incomplete sampling.</gtr:title><gtr:parentPublicationTitle>Biometrical journal. Biometrische Zeitschrift</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0116550b3dfcd7c4b2f420753b124c5"><gtr:id>a0116550b3dfcd7c4b2f420753b124c5</gtr:id><gtr:otherNames>Wolfsegger MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0323-3847</gtr:issn><gtr:outcomeId>554347CF424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FF0F06B7-2FB1-4D34-AEA8-509513FB9FBC</gtr:id><gtr:title>Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/34fd5a30cc19a4bc0f75eb8950e54f11"><gtr:id>34fd5a30cc19a4bc0f75eb8950e54f11</gtr:id><gtr:otherNames>Davies EC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>4DE010C98B3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6731007-3ED9-47FF-94AB-9EFC2851F920</gtr:id><gtr:title>Devising two-stage and multistage phase II studies on systemic adjuvant therapy for uveal melanoma.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>pm_13169_29_22743326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C9EDB6D-FB98-40FA-94D7-2E6870927C19</gtr:id><gtr:title>Incorporating children's and their parents' perspectives into condition-specific quality-of-life instruments for children with cerebral palsy: a qualitative study.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a46ff57579377a5a46babff273a4966"><gtr:id>0a46ff57579377a5a46babff273a4966</gtr:id><gtr:otherNames>Parkinson KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>BvsLChHb2T9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3D00BE2-AB59-4256-B31A-865201692150</gtr:id><gtr:title>Bayesian procedures for phase I/II clinical trials investigating the safety and efficacy of drug combinations.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>HVQFJoa2cT2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8BD4F81-E671-4BB3-8ECA-BBF46B12AB85</gtr:id><gtr:title>Adverse antiepileptic drug effects in new-onset seizures: a case-control study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c9256b6d791def0cda6248912143556"><gtr:id>3c9256b6d791def0cda6248912143556</gtr:id><gtr:otherNames>Perucca P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>mp3vHsxiJNG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6AC47E5-F05B-4963-B666-5047396A5393</gtr:id><gtr:title>Development of a database of instruments for resource-use measurement: purpose, feasibility, and design.</gtr:title><gtr:parentPublicationTitle>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cbbf8edefdbc89ec594d06a4a1c7208"><gtr:id>5cbbf8edefdbc89ec594d06a4a1c7208</gtr:id><gtr:otherNames>Ridyard CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1098-3015</gtr:issn><gtr:outcomeId>pm_13169_29_22867773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FE932A2-5C16-4B25-AAF2-DAC10ED3FC12</gtr:id><gtr:title>Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_540e15fe15f1ab11b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>829A7AB7-6C8C-4028-9C68-8E97FDC9465F</gtr:id><gtr:title>Processes in recruitment to randomised controlled trials of medicines for children (RECRUIT): a qualitative study.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f791da9a634881f30c892fc551aba1d"><gtr:id>9f791da9a634881f30c892fc551aba1d</gtr:id><gtr:otherNames>Shilling V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>YFmVgg2EU27</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50918B86-1896-4C35-BA81-FA459C4B596C</gtr:id><gtr:title>Optimal design of multi-arm multi-stage trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13169_29_22826199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1E1565D-105E-46E0-92B0-5A8F94C11318</gtr:id><gtr:title>Developing core outcome sets for clinical trials: issues to consider.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e134234ec325e4d0f2a665f60359eb6d"><gtr:id>e134234ec325e4d0f2a665f60359eb6d</gtr:id><gtr:otherNames>Williamson PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13169_29_22867278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>664CB4CF-B3EC-43A0-976A-245F113F262E</gtr:id><gtr:title>Surgical trials in head and neck oncology: Renaissance and revolution?</gtr:title><gtr:parentPublicationTitle>Head &amp; neck</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51894a6840f69d3f54f0eac83444c876"><gtr:id>51894a6840f69d3f54f0eac83444c876</gtr:id><gtr:otherNames>Shaw RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1043-3074</gtr:issn><gtr:outcomeId>545cc4d3b2bb91.63732484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17B9C99C-A21E-4D67-AB57-57C9CC905193</gtr:id><gtr:title>Sequential methods for random-effects meta-analysis.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/62f63221dc061f0b790a217a27e32074"><gtr:id>62f63221dc061f0b790a217a27e32074</gtr:id><gtr:otherNames>Higgins JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>FYo1e3hZcJS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81EB941A-F711-4D9F-8933-205B8789E745</gtr:id><gtr:title>A survey of facilitators and barriers to recruitment to the MAGNETIC trial.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9c73b502f81abc35638f4e65342b3e"><gtr:id>fb9c73b502f81abc35638f4e65342b3e</gtr:id><gtr:otherNames>Kaur G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>58a313cfc6c366.25962280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1A4870D-BE31-4A27-9959-35AB718FB5B0</gtr:id><gtr:title>Levels of epilepsy stigma in an incident population and associated factors.</gtr:title><gtr:parentPublicationTitle>Epilepsy &amp; behavior : E&amp;B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a209535e7da79b5d62367bda05695b6"><gtr:id>4a209535e7da79b5d62367bda05695b6</gtr:id><gtr:otherNames>Taylor J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-5050</gtr:issn><gtr:outcomeId>pm_13169_29_21576039</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5F5039EA-3A43-4A4E-9669-5D7476CA0746</gtr:id><gtr:title>The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/16e22d988b3228fd5fcbc4d71bb6d658"><gtr:id>16e22d988b3228fd5fcbc4d71bb6d658</gtr:id><gtr:otherNames>Jones AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>pm_13169_29_23530582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF3EC419-2CE8-4484-91F2-A154808740BB</gtr:id><gtr:title>Parents' agendas in paediatric clinical trial recruitment are different from researchers' and often remain unvoiced: a qualitative study.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef216dd99d26d1b38c076799060e74b1"><gtr:id>ef216dd99d26d1b38c076799060e74b1</gtr:id><gtr:otherNames>Woolfall K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13169_29_23844006</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD914A3D-E296-4B8D-B264-73B3C967BB3E</gtr:id><gtr:title>Reporting of harms outcomes: a comparison of journal publications with unpublished clinical study reports of orlistat trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a08194054e59e85ff83c88917190fb7e"><gtr:id>a08194054e59e85ff83c88917190fb7e</gtr:id><gtr:otherNames>Hodkinson A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>585d678b9bc810.05132212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AF198FE-9509-4795-8F9A-1C1F38FA9105</gtr:id><gtr:title>The value of source data verification in a cancer clinical trial.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>MSRf3qqqDKE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>189EE4A0-DD98-4715-ABC9-C890C4DB8B4C</gtr:id><gtr:title>Relationship of clinical and quality of life trajectories following the onset of seizures: findings from the UK MESS Study.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a34482b53e61c736de3599458cea9950"><gtr:id>a34482b53e61c736de3599458cea9950</gtr:id><gtr:otherNames>Jacoby A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>ZWC5ruN4owj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59AF5528-F5D2-42FC-9E92-8D1C30560ED2</gtr:id><gtr:title>Design of the Circulation Improving Resuscitation Care (CIRC) Trial: a new state of the art design for out-of-hospital cardiac arrest research.</gtr:title><gtr:parentPublicationTitle>Resuscitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/975adfab73260b06a017a3aeee7308b9"><gtr:id>975adfab73260b06a017a3aeee7308b9</gtr:id><gtr:otherNames>Lerner EB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-9572</gtr:issn><gtr:outcomeId>pm_13169_29_21196070</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CDF700A-A01C-407C-977A-76D7508793F6</gtr:id><gtr:title>How do parents experience being asked to enter a child in a randomised controlled trial?</gtr:title><gtr:parentPublicationTitle>BMC medical ethics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f791da9a634881f30c892fc551aba1d"><gtr:id>9f791da9a634881f30c892fc551aba1d</gtr:id><gtr:otherNames>Shilling V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1472-6939</gtr:issn><gtr:outcomeId>5783241E146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C853884-2CC3-4FFA-95C0-8B5CFCDE125C</gtr:id><gtr:title>Flexible sequential designs for multi-arm clinical trials.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/510d6ad383626fd3437a711786695ba0"><gtr:id>510d6ad383626fd3437a711786695ba0</gtr:id><gtr:otherNames>Magirr D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>54576bed5e44f5.48152903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5069D7C8-8399-46C6-8E4C-5A7328A662AF</gtr:id><gtr:title>Evaluating clinical trial designs for investigational treatments of Ebola virus disease.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/457e6907110388912b1d899289ee3a1c"><gtr:id>457e6907110388912b1d899289ee3a1c</gtr:id><gtr:otherNames>Cooper BS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>5672d01a589bb2.98052989</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93DCBB90-5BE0-42AD-99FA-782662CC0C7D</gtr:id><gtr:title>Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf633e8a9e7dec0eafc67bf8e888e532"><gtr:id>cf633e8a9e7dec0eafc67bf8e888e532</gtr:id><gtr:otherNames>Bodger K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>27F4A76F158</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>32C38FFD-C9EA-48CD-98A9-EE8A9FB8E2E1</gtr:id><gtr:title>Multi-arm clinical trials with treatment selection: what can be gained and at what price?</gtr:title><gtr:parentPublicationTitle>Clinical Investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>567a5ad383e5b4.98389975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01037064-0B73-43CC-B2DB-75A36AD820E3</gtr:id><gtr:title>The CONSENSUS study: protocol for a mixed methods study to establish which outcomes should be included in a core outcome set for oropharyngeal cancer.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/496c6f8776d1651525ea524984415a40"><gtr:id>496c6f8776d1651525ea524984415a40</gtr:id><gtr:otherNames>Waters AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_540e15fe15f30f435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4210C973-6D4D-4818-964F-C64785FB9B6C</gtr:id><gtr:title>A review of statistical designs for improving the efficiency of phase II studies in oncology.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e7c3515866026edb2920a1a6ff36e93"><gtr:id>5e7c3515866026edb2920a1a6ff36e93</gtr:id><gtr:otherNames>Wason JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>5672d37ea5dcf6.10586433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B878A5CA-D44B-4372-90A3-568D18BF7496</gtr:id><gtr:title>What parents of children who have received emergency care think about deferring consent in randomised trials of emergency treatments: postal survey.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d21017d656b537490aad9baf03f046fc"><gtr:id>d21017d656b537490aad9baf03f046fc</gtr:id><gtr:otherNames>Gamble C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13169_29_22586456</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9BED1432-095B-4226-880A-E03E705DF7BF</gtr:id><gtr:title>Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children.</gtr:title><gtr:parentPublicationTitle>Pediatrics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe5f56f8960ed3ede9d724858b2d06d"><gtr:id>cbe5f56f8960ed3ede9d724858b2d06d</gtr:id><gtr:otherNames>Sinha IP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0031-4005</gtr:issn><gtr:outcomeId>pm_13169_29_22661761</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DF90500-4DB8-4063-ACBF-78148249EC67</gtr:id><gtr:title>Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with cystic fibrosis.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/323902f103f9821ffddfd9c683a2e6fc"><gtr:id>323902f103f9821ffddfd9c683a2e6fc</gtr:id><gtr:otherNames>Hickey HR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>qcueuPsKcUP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0111721D-121A-4AE4-94E0-CB33D62FCEF2</gtr:id><gtr:title>Nonadherence to treatment protocol in published randomised controlled trials: a review.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/001663d69b738304faf38b5a13e5c02c"><gtr:id>001663d69b738304faf38b5a13e5c02c</gtr:id><gtr:otherNames>Dodd S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13169_29_22709676</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8E14002E-5717-4FF1-8586-7D103D469DF3</gtr:id><gtr:title>Analysing malaria drug trials on a per-individual or per-clone basis: a comparison of methods.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13169_29_23258694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3999075-A86C-4394-B20C-058DEAE0BFC4</gtr:id><gtr:title>The COMET (Core Outcome Measures in Effectiveness Trials) Initiative: Its Role in Improving Cochrane Reviews.</gtr:title><gtr:parentPublicationTitle>The Cochrane database of systematic reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d11b1cc1261bcf10b944064d7fc9f65c"><gtr:id>d11b1cc1261bcf10b944064d7fc9f65c</gtr:id><gtr:otherNames>Williamson P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1361-6137</gtr:issn><gtr:outcomeId>pm_13169_29_22592744</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC9BBDB2-F8E8-4256-A581-D5A0F895E0C4</gtr:id><gtr:title>Can a core outcome set improve the quality of systematic reviews?--a survey of the Co-ordinating Editors of Cochrane Review Groups.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a17f519190d217d4e666d854dbdf4787"><gtr:id>a17f519190d217d4e666d854dbdf4787</gtr:id><gtr:otherNames>Kirkham JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>pm_13169_29_23339751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>831FFF60-7FBA-4980-AD91-3BD4DE2942F7</gtr:id><gtr:title>Seeking consent to tissue banking: a survey of health professionals in childhood cancer.</gtr:title><gtr:parentPublicationTitle>European journal of cancer care</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e34e78f3be6717209b698907c5d8f735"><gtr:id>e34e78f3be6717209b698907c5d8f735</gtr:id><gtr:otherNames>Jackson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0961-5423</gtr:issn><gtr:outcomeId>1F90DC36A77</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68193987-517C-4F9F-BEA3-96184E6638A5</gtr:id><gtr:title>Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1f2122640ae0c1eeb2718fb1cb8899"><gtr:id>6f1f2122640ae0c1eeb2718fb1cb8899</gtr:id><gtr:otherNames>Hampson LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>doi_55f984984c249f6a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F154C82-A4B4-4F37-AD75-F4F14ADC3532</gtr:id><gtr:title>A systematic review and empirical analysis of the relation between dose and duration of drug action.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3b59c01318db7c233a9f9e667e937a"><gtr:id>4f3b59c01318db7c233a9f9e667e937a</gtr:id><gtr:otherNames>Hughes DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0091-2700</gtr:issn><gtr:outcomeId>ED534C9A734</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B708AC1D-0238-438B-BE1D-2137F0ED96E3</gtr:id><gtr:title>A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/929c01fad63b4752722556c629106f10"><gtr:id>929c01fad63b4752722556c629106f10</gtr:id><gtr:otherNames>Cotterill A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>5672d11f1621b4.75656586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D675B34-4C4B-43D3-BFD7-9B574466864E</gtr:id><gtr:title>Block response-adaptive randomization in clinical trials with binary endpoints</gtr:title><gtr:parentPublicationTitle>Pharmaceutical Statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/510d6ad383626fd3437a711786695ba0"><gtr:id>510d6ad383626fd3437a711786695ba0</gtr:id><gtr:otherNames>Magirr D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>Yo2mvJBmMm2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE7942D2-1A64-43CD-8D73-38482D4EBE03</gtr:id><gtr:title>Assessment of the quality of harms reporting in non-randomised studies and randomised controlled studies of topiramate for the treatment of epilepsy using CONSORT criteria.</gtr:title><gtr:parentPublicationTitle>Epilepsy research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5d9df606cc305eec1859fd5b796d35c"><gtr:id>d5d9df606cc305eec1859fd5b796d35c</gtr:id><gtr:otherNames>Carmichael K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0920-1211</gtr:issn><gtr:outcomeId>56b0c90e85ef46.00072522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E31F3F2-177C-44D1-A317-47B04B7446A9</gtr:id><gtr:title>An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Pancreas</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a09c285d577593f3daba5181659f00e"><gtr:id>4a09c285d577593f3daba5181659f00e</gtr:id><gtr:otherNames>Gilliam AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0885-3177</gtr:issn><gtr:outcomeId>pm_13169_29_22228104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4851C9B7-AF99-42A2-A6DA-B1B3FB7C2772</gtr:id><gtr:title>From NCE to NICE: the role of pharmacoeconomics.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3b59c01318db7c233a9f9e667e937a"><gtr:id>4f3b59c01318db7c233a9f9e667e937a</gtr:id><gtr:otherNames>Hughes DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>HL1YzUkwtM8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EE7F85C-61F0-4B13-9710-FD88EC140617</gtr:id><gtr:title>A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6a711a4a781bbb5f95a62d5b0aee603b"><gtr:id>6a711a4a781bbb5f95a62d5b0aee603b</gtr:id><gtr:otherNames>Sinha I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>7EB14B43C2B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>586E1767-B1F2-4477-82A8-2F3C509B35D1</gtr:id><gtr:title>How should individual participant data (IPD) from publicly funded clinical trials be shared?</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>56b0c90dac1e66.96174192</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70684008-4713-4477-B306-29FAE0088AC6</gtr:id><gtr:title>Using historical lesion volume data in the design of a new phase II clinical trial in acute stroke.</gtr:title><gtr:parentPublicationTitle>Stroke</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0039-2499</gtr:issn><gtr:outcomeId>BF24CC946FA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDF2B346-9B85-4152-A785-019AF8DD9B0E</gtr:id><gtr:title>Interventions to improve recruitment and retention in clinical trials: a survey and workshop to assess current practice and future priorities.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ded55b189099956a0ac27e9da424f376"><gtr:id>ded55b189099956a0ac27e9da424f376</gtr:id><gtr:otherNames>Bower P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>545355f15077e2.30803484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D8AB52FB-ACC2-4B4D-BFC9-2B65EDD584AD</gtr:id><gtr:title>A Bayesian approach to dose-finding studies for cancer therapies: incorporating later cycles of therapy.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98dad08937c6b1f24bb89a872f114f3f"><gtr:id>98dad08937c6b1f24bb89a872f114f3f</gtr:id><gtr:otherNames>Sinclair K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>545353d49f8ab0.04270934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64B0C07B-D808-4D04-9730-2C07018A7A42</gtr:id><gtr:title>Women's experiences of participating in the Magpie Trial: a postal survey in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Birth (Berkeley, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bd7807b7e314ccca158a271ae22f156"><gtr:id>6bd7807b7e314ccca158a271ae22f156</gtr:id><gtr:otherNames>Smyth RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0730-7659</gtr:issn><gtr:outcomeId>DE4FEB8C91F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8929A83-1F38-4CC2-A5FF-35DDCACA3A3B</gtr:id><gtr:title>Group sequential trials revisited: simple implementation using SAS.</gtr:title><gtr:parentPublicationTitle>Statistical methods in medical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0962-2802</gtr:issn><gtr:outcomeId>pm_13169_29_20876163</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5FAB30E-DAFC-4CBB-953C-7F5AF0136A8F</gtr:id><gtr:title>A simple two-stage design for quantitative responses with application to a study in diabetic neuropathic pain.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>aATSakPY51X</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7BD6E18-31CC-4973-BB21-78AADB3896D2</gtr:id><gtr:title>Questioning assent: how are children's views included as families make decisions about clinical trials?</gtr:title><gtr:parentPublicationTitle>Child: care, health and development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0fbbea275d6bcc01f7beee52fd041848"><gtr:id>0fbbea275d6bcc01f7beee52fd041848</gtr:id><gtr:otherNames>Madden L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1862</gtr:issn><gtr:outcomeId>58a42fd0501ba7.45557597</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1ED2FCD-D0E8-4B45-B589-C9649B18D8C9</gtr:id><gtr:title>The trials methodological research agenda: results from a priority setting exercise.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e74e8623ca55eface3c41e51bceb20"><gtr:id>63e74e8623ca55eface3c41e51bceb20</gtr:id><gtr:otherNames>Tudur Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>doi_55f984984c10e02f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EEB70B82-CDBF-41FD-B67D-E5057590622A</gtr:id><gtr:title>Taxonomy for methods of resource use measurement.</gtr:title><gtr:parentPublicationTitle>Health economics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cbbf8edefdbc89ec594d06a4a1c7208"><gtr:id>5cbbf8edefdbc89ec594d06a4a1c7208</gtr:id><gtr:otherNames>Ridyard CH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1057-9230</gtr:issn><gtr:outcomeId>585d31c2b148a7.48533390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6C37838-F761-4A88-98CE-8AAA3E5C0E64</gtr:id><gtr:title>Incorporating prognostic factors into causal estimators: a comparison of methods for randomised controlled trials with a time-to-event outcome.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1f2122640ae0c1eeb2718fb1cb8899"><gtr:id>6f1f2122640ae0c1eeb2718fb1cb8899</gtr:id><gtr:otherNames>Hampson LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13169_29_22714785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0FD9F25-440C-4BE9-B9D3-6CEA9F1C91F8</gtr:id><gtr:title>Considerations on covariates and endpoints in multi-arm multi-stage clinical trials selecting all promising treatments.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7faa0b927774aec35159186f2d5a247c"><gtr:id>7faa0b927774aec35159186f2d5a247c</gtr:id><gtr:otherNames>Jaki T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>pm_13169_29_23112135</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F563516F-AD6C-4509-9FBF-8C7AF90F77DE</gtr:id><gtr:title>Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter?</gtr:title><gtr:parentPublicationTitle>Clinical trials (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/982fc5363b94ff9a1c1c8d8352ef89c4"><gtr:id>982fc5363b94ff9a1c1c8d8352ef89c4</gtr:id><gtr:otherNames>Hollingworth W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1740-7745</gtr:issn><gtr:outcomeId>pm_13169_29_23231969</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56CF2971-3715-4FCB-AE0B-59547390CDF7</gtr:id><gtr:title>Prognostic factors for epilepsy</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cf991c90d48bf257b1d64087109be221"><gtr:id>cf991c90d48bf257b1d64087109be221</gtr:id><gtr:otherNames>Bonnett Laura</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>58c7c0ed621859.53931487</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9C5E4D8-C594-494B-AABA-68A447309632</gtr:id><gtr:title>Using regression mixture models with non-normal data: Examining an ordered polytomous approach.</gtr:title><gtr:parentPublicationTitle>Journal of statistical computation and simulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31009ae23aead131001ee1056b6c684b"><gtr:id>31009ae23aead131001ee1056b6c684b</gtr:id><gtr:otherNames>George MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0094-9655</gtr:issn><gtr:outcomeId>pm_13169_29_23687397</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>82B4493A-545B-4ED7-9790-2CD97814F09F</gtr:id><gtr:title>UK publicly funded Clinical Trials Units supported a controlled access approach to share individual participant data but highlighted concerns.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50c53ac5efc52c6e7ca263d0bf9ed86a"><gtr:id>50c53ac5efc52c6e7ca263d0bf9ed86a</gtr:id><gtr:otherNames>Hopkins C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>56b0c90e14f515.79078336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1BE0204-080B-4551-844F-740E4036D1BE</gtr:id><gtr:title>Pharmacoeconomics.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f3b59c01318db7c233a9f9e667e937a"><gtr:id>4f3b59c01318db7c233a9f9e667e937a</gtr:id><gtr:otherNames>Hughes DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>pm_13169_29_22360714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D00404F-FD6F-46B5-8FEC-8E0C8B945FA5</gtr:id><gtr:title>How individual participant data meta-analyses have influenced trial design, conduct, and analysis.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/663c60b99db378e47bc2ef1efd6bb108"><gtr:id>663c60b99db378e47bc2ef1efd6bb108</gtr:id><gtr:otherNames>Tierney JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn><gtr:outcomeId>56b0c90e4bfb89.88687671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7575C7E-F397-4365-9E95-9E017022DF00</gtr:id><gtr:title>One-stage and two-stage designs for phase II clinical trials with survival endpoints.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>545353d4790421.61796739</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24ECDCE1-8891-4325-9909-084B5257212F</gtr:id><gtr:title>Outcomes in clinical trials of inhaled corticosteroids for children with asthma are narrowly focussed on short term disease activity.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cbe5f56f8960ed3ede9d724858b2d06d"><gtr:id>cbe5f56f8960ed3ede9d724858b2d06d</gtr:id><gtr:otherNames>Sinha IP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>8FD092AB347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B90FE3E6-5337-4C8D-9C09-5CBB1523FF37</gtr:id><gtr:title>Driving up the quality and relevance of research through the use of agreed core outcomes.</gtr:title><gtr:parentPublicationTitle>Journal of health services research &amp; policy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d11b1cc1261bcf10b944064d7fc9f65c"><gtr:id>d11b1cc1261bcf10b944064d7fc9f65c</gtr:id><gtr:otherNames>Williamson P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1355-8196</gtr:issn><gtr:outcomeId>pm_13169_29_22294719</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E16FB4CF-49D7-4CCD-B410-58E8796C6093</gtr:id><gtr:title>Development of a core outcome set for research and audit studies in reconstructive breast surgery.</gtr:title><gtr:parentPublicationTitle>The British journal of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/217edbad5ea0e4d19bb1e17ecd503e55"><gtr:id>217edbad5ea0e4d19bb1e17ecd503e55</gtr:id><gtr:otherNames>Potter S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1323</gtr:issn><gtr:outcomeId>5675e89c754c9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E332E0B4-2B11-4625-9D35-910C05F66A9C</gtr:id><gtr:title>Interpreting regulatory trials in epilepsy.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/310430b95f1a4b8baa2dfb2c52c994d9"><gtr:id>310430b95f1a4b8baa2dfb2c52c994d9</gtr:id><gtr:otherNames>Marson AG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1350-7540</gtr:issn><gtr:outcomeId>F5D99A09CE0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B092830-5FA4-4C26-8C0F-0D04B22B4B26</gtr:id><gtr:title>A Bayesian dose-finding procedure for phase I clinical trials based only on the assumption of monotonicity.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd07d27aa98f25db14362e53335a0653"><gtr:id>dd07d27aa98f25db14362e53335a0653</gtr:id><gtr:otherNames>Whitehead J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn><gtr:outcomeId>kAmVe6yGoWn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75BC3DE6-7DF4-4913-B344-1C6432271572</gtr:id><gtr:title>Communication about children's clinical trials as observed and experienced: qualitative study of parents and practitioners.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f791da9a634881f30c892fc551aba1d"><gtr:id>9f791da9a634881f30c892fc551aba1d</gtr:id><gtr:otherNames>Shilling V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>jTX8764dyma</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFC6D84D-C71F-4643-96E4-88C9F324CDAD</gtr:id><gtr:title>Making co-enrolment feasible for randomised controlled trials in paediatric intensive care.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66f80192119d5ee3ba51bad3c6e4af25"><gtr:id>66f80192119d5ee3ba51bad3c6e4af25</gtr:id><gtr:otherNames>Harron K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13169_29_22870249</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>30DAAB0B-E538-4A8E-814C-2970580C6610</gtr:id><gtr:title>The use of qualitative methods to inform Delphi surveys in core outcome set development.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26a02c8ac740b6e5834f02387a5ba7b0"><gtr:id>26a02c8ac740b6e5834f02387a5ba7b0</gtr:id><gtr:otherNames>Keeley T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>585d5030ebeb74.52491404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6180C6E-3CE2-463B-903F-3A05E28D0B1E</gtr:id><gtr:title>Defining rewardable innovation in drug therapy.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Drug discovery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c74d7c52f364adfcff677b5cf0dc6b9d"><gtr:id>c74d7c52f364adfcff677b5cf0dc6b9d</gtr:id><gtr:otherNames>Aronson JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1474-1776</gtr:issn><gtr:outcomeId>pm_13169_29_22460109</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07ED8DE0-1593-449C-A17F-11F84BAD1EB5</gtr:id><gtr:title>Barriers to recruitment for surgical trials in head and neck oncology: a survey of trial investigators.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fb9c73b502f81abc35638f4e65342b3e"><gtr:id>fb9c73b502f81abc35638f4e65342b3e</gtr:id><gtr:otherNames>Kaur G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>pm_13169_29_23585392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E09E1DF4-BC7A-4A3D-8AA2-828EF7B3AF24</gtr:id><gtr:title>Balancing high accrual and ethical recruitment in paediatric oncology: a qualitative study of the 'look and feel' of clinical trial discussions.</gtr:title><gtr:parentPublicationTitle>BMC medical research methodology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66bca9cfa1f94cfc4f5a05ca02e58788"><gtr:id>66bca9cfa1f94cfc4f5a05ca02e58788</gtr:id><gtr:otherNames>Byrne-Davis LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1471-2288</gtr:issn><gtr:outcomeId>fRPpBjzm1aZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F1B211C-DE0D-4204-A351-5BD5CBC4E68E</gtr:id><gtr:title>Evidence for the selective reporting of analyses and discrepancies in clinical trials: a systematic review of cohort studies of clinical trials.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92032a2603eb4aabc998973c797e3802"><gtr:id>92032a2603eb4aabc998973c797e3802</gtr:id><gtr:otherNames>Dwan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn><gtr:outcomeId>545355f0a866f4.61377659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81AC9D20-CECF-4623-804D-F23EF89322D6</gtr:id><gtr:title>An evaluation of methods for testing hypotheses relating to two endpoints in a single clinical trial.</gtr:title><gtr:parentPublicationTitle>Pharmaceutical statistics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/afe1da4e5da37f2247faa9dd957b21ea"><gtr:id>afe1da4e5da37f2247faa9dd957b21ea</gtr:id><gtr:otherNames>Su TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1539-1604</gtr:issn><gtr:outcomeId>pm_13169_29_22337619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A43A05DE-73F0-439C-8A58-BF12C5829E49</gtr:id><gtr:title>Factors predictive of resilience and vulnerability in new-onset epilepsy.</gtr:title><gtr:parentPublicationTitle>Epilepsia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4a209535e7da79b5d62367bda05695b6"><gtr:id>4a209535e7da79b5d62367bda05695b6</gtr:id><gtr:otherNames>Taylor J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0013-9580</gtr:issn><gtr:outcomeId>rePHD3kaCgG</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C91B4707-828D-4CB7-ABF2-BA270FBE013A</gtr:id><gtr:title>An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes.</gtr:title><gtr:parentPublicationTitle>BMC family practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59b2eac2fb9616749f5baa65271de9fd"><gtr:id>59b2eac2fb9616749f5baa65271de9fd</gtr:id><gtr:otherNames>Farmer A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1471-2296</gtr:issn><gtr:outcomeId>pm_13169_29_22480341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDF71701-9205-45BD-853B-F81F35347A5A</gtr:id><gtr:title>Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6535ed7c52ea3cd73477e3e1c512cc91"><gtr:id>6535ed7c52ea3cd73477e3e1c512cc91</gtr:id><gtr:otherNames>Pushpakom SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn><gtr:outcomeId>567a5c6c2f82f5.61305792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>091A7B1D-9274-45B1-87E8-CFB8B06897C7</gtr:id><gtr:title>Evaluation of interventions for informed consent for randomised controlled trials (ELICIT): protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bba43e2a9bd94bb13461955a658f289b"><gtr:id>bba43e2a9bd94bb13461955a658f289b</gtr:id><gtr:otherNames>Gillies K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>585d5659b35a50.40267099</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9CC6B36-BE9C-45B3-BDFA-DAE7F5EFAA34</gtr:id><gtr:title>Bridging the gap: a review of dose investigations in paediatric investigation plans.</gtr:title><gtr:parentPublicationTitle>British journal of clinical pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6f1f2122640ae0c1eeb2718fb1cb8899"><gtr:id>6f1f2122640ae0c1eeb2718fb1cb8899</gtr:id><gtr:otherNames>Hampson LV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0306-5251</gtr:issn><gtr:outcomeId>545353d450a8f8.64180943</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800792</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>B3B786B2-60C5-4A01-808F-859CEE871296</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.5  Resources and infrastructure (health services)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>